Industry news

U.K. team links cancer cell shape, gene expression and clinical outcomes

Amirah Al Idrus / Fierce Biotech

Cancer cells are continually changing shape in response to their surrounding environment. Scientists at the Institute of Cancer Research in London have created “maps” linking this shape-changing to alterations in gene expression and real-world outcomes in breast cancer.

Report cards could be just what pharma needs to get back to respectability

Beth Snyder Bulik / FiercePharmaMarketing

In 1997, 79% of people in the U.S. believed pharma companies were honest and ethical. Today that percentage has plummeted to just 10%. But one researcher has an idea about how to reverse the slide. Take a page from other beleaguered industries and establish a transparent ratings system, says Jennifer Miller, founder of independent nonprofit ethics reviewer Bioethics International and an assistant professor at New York University School of Medicine. 

Big Pharma promised Trump new American jobs for tax cuts and deregulation. But the vow comes after a 5-year purge

John Carroll / Endpoints News

Several Big Pharma chiefs joined Bradway for the session with Trump. And in most cases, they represent global companies that have been bending over backwards to rein in R&D costs and hold the line on spending, particularly in the US. In a couple of cases, you’ll find some heavy job losses globally, with major cuts directed at US workforces.

Path of Uncertainty: Pharm Exec’s 2017 Industry Forecast

Julian Upton, Casey McDonald / Pharmaceutical Executive

The populist-driven shifts sweeping the US and EU have triggered plenty of questions when trying to assess the outlook for the global life sciences industry. One certainty, however, amid post-Trump victory and pro-Brexit mandates, will be change, as Pharm Exec’s annual industry forecast explores. 

01 February 2017

Marinus Appoints Michael R. Dougherty to its Board of Directors

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the appointment of Michael R. Dougherty to its Board of Directors.

Market Access 2017: A European Perspective

Julian Upton / Pharmaceutical Executive

Pharm Exec speaks to Ramita Tandon, Executive Vice President, ICON Commercialization & Outcomes, about how the UK and European regulators' market access plans for 2017 will affect the industry.

Report: FDA New Drug Approvals Dip in 2016

BioPharm International

FDA approval of new molecular entities (NMEs) took a sharp decline in 2016 according to a new report released in January 2017 from HBM Partners. In 2016 FDA approved 19 new therapeutic drugs compared to 45 in 2015, the report noted. The official number of novel drugs approved by FDA’s Center for Drug Evaluation and Research (CDER) in 2016 was 22, but this number includes two imaging agents and one antidote, which were not included in the HBM report number.

Pfizer CEO says no need to alter its drug pricing practices

Bill Berkrot / Reuters

Pfizer Inc (PFE.N) Chief Executive Ian Read said on Tuesday the company would not change its philosophy on pricing of its medicines or when it takes price increases, bucking a recent trend by some rivals of the largest U.S. drugmaker.

31 January 2017

Syndax Appoints Lisa M. Coussens, Ph.D., to Scientific Advisory Board

Syndax Pharmaceuticals, Inc. ("Syndax," the “Company” or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced the appointment of Lisa M. Coussens, Ph.D., to its Scientific Advisory Board.

Ban DTC or fix it? Docs sound off about patient confusion over ads

Beth Snyder Bulik / FiercePharmaMarketing